Sweden-based Anocca Secures USD46M Funding

The funding round was led by Mellby Gård, with participation from AMF, Ramsbury, existing shareholders, and additional new investors.

The company plans to use the funds to advance VIDAR-1, its gene-edited TCR-T cell therapy targeting mutant KRAS in pancreatic cancer, through early-stage clinical trials. The funding will also support the development of its preclinical pipeline.

Read Also - Berlin-based WALLROUND Raises €4.2 Million Funding

Led by CEO Reagan Jarvis, Anocca is a clinical-stage biopharmaceutical company focused on developing T-cell receptor-engineered T cell (TCR-T) therapies to treat solid tumors and other challenging conditions, including infectious and autoimmune diseases.

The company has created a discovery engine using programmable human cells to replicate and modify T cell immunity. These proprietary technologies allow Anocca to scale TCR-T therapy development, systematically generating libraries of personalized treatment options for diverse patient populations.

Reagan Jarvis, co-founder and CEO of Anocca, said, “We thank our investors for their strong and continued support as we advance our first TCR-T cell therapy products into the clinic. The team has built a unique discovery platform and in-house manufacturing capability, and we are now excited to see the first products reaching patients with high unmet need.”

The company operates an advanced R&D infrastructure supported by a custom software ecosystem, AnoccaOS, alongside in-house cGMP manufacturing and process development facilities. All therapeutic TCRs are novel discoveries from its platform and are produced using non-viral gene-editing technology at Anocca’s Swedish facilities.

About Anocca

Founded in 2014, Anocca is a biopharmaceutical company developing TCR-T cell therapies for solid tumors, infectious, and autoimmune diseases. Its proprietary discovery engine and AnoccaOS platform enable scalable, personalized treatments, supported by in-house cGMP manufacturing and non-viral gene-editing technology at its Swedish facilities.